Bibliografie tematiche / Resistance to therapies / Libri
Segui questo link per vedere altri tipi di pubblicazioni sul tema: Resistance to therapies.

Libri sul tema "Resistance to therapies"

Autore: Grafiati
Pubblicato: 16 novembre 2024

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 libri per l'attività di ricerca sul tema "Resistance to therapies".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi i libri di molte aree scientifiche e compila una bibliografia corretta.

1

Xavier, Ana C., e Mitchell S. Cairo, a cura di. Resistance to Targeted Therapies in Lymphomas. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-24424-8.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Ling, Silvia CW, e Steven Trieu, a cura di. Resistance to Targeted Therapies in Multiple Myeloma. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73440-4.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Villanueva, Augusto, a cura di. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56197-4.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Prosperi, Jenifer R., a cura di. Resistance to Targeted Therapies in Breast Cancer. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-70142-4.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Tivnan, Amanda, a cura di. Resistance to Targeted Therapies Against Adult Brain Cancers. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46505-0.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Szewczuk, Myron R., Bessi Qorri e Manpreet Sambi, a cura di. Current Applications for Overcoming Resistance to Targeted Therapies. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21477-7.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Ferreri, Andrés J. M., a cura di. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-75184-9.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20741-4.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Scardino, Peter T. Targeted Therapies for Castration-Resistant Prostate Cancer. Unitec House, 2 Albert Place, London N3 1QB, UK: Future Medicine Ltd, 2011. http://dx.doi.org/10.2217/9781780840109.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Michael, Neenan, a cura di. Working with resistance in rational emotive behaviour therapy: A practitioner's guide. London: Routledge, 2012.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
11

Targeted Therapies: Mechanisms of Resistance. Humana, 2013.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
12

Targeted therapies: Mechanisms of resistance. New York: Humana Press, 2011.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
13

Gioeli, Daniel. Targeted Therapies: Mechanisms of Resistance. Humana Press, 2011.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
14

Cairo, Mitchell S., e Ana C. Xavier. Resistance to Targeted Therapies in Lymphomas. Springer International Publishing AG, 2020.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
15

Cairo, Mitchell S., e Ana C. Xavier. Resistance to Targeted Therapies in Lymphomas. Springer, 2019.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
16

Lasfar, Ahmed, Andrew Zloza, Karine A. Cohen-Solal e Murugabaskar Balan, a cura di. Tumor Microenvironment and Resistance to Current Therapies. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-283-1.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
17

Prosperi, Jenifer R. Resistance to Targeted Therapies in Breast Cancer. Springer, 2017.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
18

Ling, Silvia, e Steven Trieu. Resistance to Targeted Therapies in Multiple Myeloma. Springer International Publishing AG, 2021.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
19

Villanueva, Augusto. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Springer, 2017.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
20

Prosperi, Jenifer R. Resistance to Targeted Therapies in Breast Cancer. Springer, 2018.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
21

Villanueva, Augusto. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Springer, 2018.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
22

Ling, Silvia Cw, e Steven Trieu. Resistance to Targeted Therapies in Multiple Myeloma. Springer International Publishing AG, 2022.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
23

Szewczuk, Myron R., Bessi Qorri e Manpreet Sambi. Current Applications for Overcoming Resistance to Targeted Therapies. Springer, 2019.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
24

Ferreri, Andrés J. M. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Springer International Publishing AG, 2019.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
25

Tivnan, Amanda. Resistance to Targeted Therapies Against Adult Brain Cancers. Springer, 2016.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
26

Szewczuk, Myron R., Bessi Qorri e Manpreet Sambi. Current Applications for Overcoming Resistance to Targeted Therapies. Springer International Publishing AG, 2020.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
27

Ferreri, Andrés J. M. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Springer, 2018.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
28

Tivnan, Amanda. Resistance to Targeted Therapies Against Adult Brain Cancers. Springer, 2018.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
29

Bonavida, Benjamin. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance. Springer New York, 2015.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
30

Molecular Mechanisms Of Tumor Cell Resistance To Chemotherapy Targeted Therapies To Reverse Resistance. Springer-Verlag New York Inc., 2013.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
31

Bonavida, Benjamin. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance. Springer London, Limited, 2013.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
32

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Springer International Publishing AG, 2015.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
33

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Adis International, Limited, 2015.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
34

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne e Gareth Morris-Stiff. Targeted and biological therapies. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0009.

Testo completo
Abstract (sommario):
Hormone therapy describes the role of hormones in the growth of a variety of cancers, and the therapeutic effects of manipulation of hormone levels in these diseases. Sex hormones stimulate the growth of breast and prostate cancers, many of which respond to surgical removal of the hormone-secreting gonad. Pharmacological measures to deliver hormone therapy in these diseases include luteinising hormone releasing hormone (LHRH) agonists and antagonists, inhibitors of sex hormone synthesis, and inhibitors of hormone-receptor binding. These treatments have established benefits in both in the control of advanced disease and the adjuvant therapy of early-stage disease. The pros and cons of combination hormone therapy are discussed. Resistance to hormone therapy may be primary or acquired, and the likely mechanisms are described.
Gli stili APA, Harvard, Vancouver, ISO e altri
35

Fraziano, Maurizio, Roberto Nisini, Gian Maria Rossolini e Marco Rinaldo Oggioni, a cura di. Exploiting Novel Combined Host- and Pathogen-Directed Therapies for Combating Bacterial Multidrug Resistance. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88966-307-1.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
36

Ensell, Alden. Insulin Resistance Diet - Combat Pcos Problems, Daily Food Plans, Proper Lifestyle and Tasty Recipes: Pcos and Natural Therapies. Independently Published, 2021.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
37

Poma, Alessandro, e Loris Rizzello. Nanotechnology Tools for Infections Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance. Elsevier, 2022.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
38

Poma, Alessandro, e Loris Rizzello. Nanotechnology Tools for Infections Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance. Elsevier, 2022.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
39

Howland, Robert H. Multidisciplinary Treatments and Medications for Depressive Disorders and Comorbidity. A cura di C. Steven Richards e Michael W. O'Hara. Oxford University Press, 2014. http://dx.doi.org/10.1093/oxfordhb/9780199797004.013.008.

Testo completo
Abstract (sommario):
Compared with episodic depression, chronic depression and treatment resistant depression have higher rates of comorbidity, more persistent social and vocational disability, an increased risk of suicide, greater medical morbidity and mortality, and greater health care utilization and costs. A large number of antidepressant medications and other psychotropic drugs, depression-focused psychotherapies, and neuromodulation therapies are available for the treatment of depression. Many drugs or psychotherapies are used for the treatment of other psychiatric disorders or medical conditions, and they should be considered relevant when these comorbidities exist with depression. Selecting treatments for depression must take into account the clinical implications of the presence of any comorbidities. Because comorbidity is associated with depressive chronicity and treatment resistance, various approaches to treating chronic depression or TRD have been investigated. Treating depressed patients with comorbid psychiatric, personality, or medical disorders is a clinical challenge that requires effective multidisciplinary collaboration.
Gli stili APA, Harvard, Vancouver, ISO e altri
40

Murrough, James. Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation. Elsevier Science & Technology Books, 2024.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
41

Murrough, James. Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation. Elsevier Science & Technology, 2024.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
42

Stafstrom, Carl E. Alternative Therapies for Epilepsy. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0046.

Testo completo
Abstract (sommario):
Up to one third of patients with epilepsy suffer from seizures that are refractory to medications. For these patients, many of whom are not surgical candidates, dietary therapies provide a promising alternative. The best known dietary therapy is the ketogenic diet, which was developed in the 1920s; newer variants of the ketogenic diet, such as the medium-chain triglyceride diet, modified Atkins diet, and low glycemic index treatment, afford excellent seizure control with fewer dietary restrictions. Together, dietary approaches offer drug-resistant patients hope for seizure reduction and an improved quality of life.
Gli stili APA, Harvard, Vancouver, ISO e altri
43

Fu, Caiyun, Yongchuan Gu, Hong Zhu, Wen Zhou e Fanfan Zhou, a cura di. Clinical Therapeutic Development Against Cancers Resistant to Targeted Therapies. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-428-2.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
44

Kreit, John W. Severe Obstructive Lung Disease. A cura di John W. Kreit. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190670085.003.0013.

Testo completo
Abstract (sommario):
Although chronic obstructive lung disease, asthma, bronchiectasis, and bronchiolitis have very different causes, clinical features, and therapies, they share the same underlying pathophysiology. They are referred to as obstructive lung diseases because airway narrowing causes increased resistance and slowing of expiratory gas flow. Mechanical ventilation of patients with severe obstructive lung disease often produces two problems that must be recognized and effectively managed: over-ventilation and dynamic hyperinflation. Severe Obstructive Lung Disease reviews these two major adverse consequences of mechanical ventilation in patients with severe air flow obstruction. The chapter explains how to detect and correct both of these problems and provides guidelines for managing patients with respiratory failure caused by severe obstructive lung disease.
Gli stili APA, Harvard, Vancouver, ISO e altri
45

León-Buitimea, Angel, Jose Ruben Morones-Ramirez, Jason H. Yang e Rafael Peña-Miller, a cura di. Facing the Upcoming of Multidrug-Resistant and Extensively Drug-Resistant Bacteria: Novel Antimicrobial Therapies (NATs). Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88966-653-9.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
46

Kessler, Sudha Kilaru. The Ketogenic Diet and Related Therapies in “Novel” Situations. A cura di Eric H. Kossoff. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190497996.003.0008.

Testo completo
Abstract (sommario):
The ketogenic diet (KD) is often considered as a treatment option for medication-resistant focal epilepsies and symptomatic generalized epilepsies, but is perhaps less commonly considered for idiopathic generalized epilepsies. The evidence for the use of the KD in two common idiopathic generalized epilepsy syndromes, childhood absence epilepsy and juvenile myoclonic epilepsy, is presented here.
Gli stili APA, Harvard, Vancouver, ISO e altri
47

Demitrack, Mark A., e Sarah H. Lisanby. Methodological issues in clinical trial design for TMS. A cura di Charles M. Epstein, Eric M. Wassermann e Ulf Ziemann. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780198568926.013.0039.

Testo completo
Abstract (sommario):
This article explores the emergence of transcranial magnetic stimulation (TMS) as a new therapeutic approach and the implications of this technology for the study and treatment of neuropsychiatric disorders, with a focus on major depression. Relapse, chronicity, and varying degrees of treatment resistance characterize major depression. A substantial number of patients are not effectively treated with pharmacology or medications alone. It is proposed that TMS, along with other device-based therapies emerging in psychiatry, may define a potential new treatment platform, with existing therapeutics for major depression. Through the example of a study, this article describes the methodological considerations in the development of TMS for the treatment of major depression. Device-based approaches to therapeutic neuromodulation hold the promise of significant clinical advantages compared to existing treatments for major depression, but evidence in well designed and properly blinded multicenter trials is still lacking, hence, research in this area is ongoing.
Gli stili APA, Harvard, Vancouver, ISO e altri
48

Shapiro, Leslie J. Understanding OCD. ABC-CLIO, LLC, 2015. http://dx.doi.org/10.5040/9798216029649.

Testo completo
Abstract (sommario):
One of the most experienced therapists in the world for treatment-resistant obsessive compulsive disorder (OCD) explains the disorder, the treatments available, and the skills needed to overcome and outsmart OCD. This is an eye-opening study of one of the most common psychiatric ailments diagnosed today—obsessive compulsive disorder (OCD). Written by Leslie J. Shapiro, a renowned therapist at one of the most well known OCD facilities in the world, this reference shares effective treatment strategies and clinical factors for helping therapists, mental health professionals, psychology students, clergy, and others deal with patients coping with this illness. The author offers case examples from her 15 years of residential work with patients, demonstrating how sufferers—even the most treatment resistant—can get control of the condition. Organized into three sections, this guidebook first reveals how OCD and guilt are intertwined and explores survival instincts, cultural factors, and the nature of thoughts. The second section covers aspects of the obsessive conscience such as scrupulosity, moralosity, and obsessive guilt. The book’s conclusion describes effective exposure and response prevention strategies for these symptoms and examines methods of treatment that augment and help maintain recovery. An in-depth discussion on the differences between compulsive and impulsive behaviors—as well as other treatment impediments—is included.
Gli stili APA, Harvard, Vancouver, ISO e altri
49

Mukherji, Deborah, Aurelius Omlin, Carmel Pezaro e Johann De Bono. Novel therapies and emerging strategies for the treatment of patients with castration-resistant prostate cancer. A cura di James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0069.

Testo completo
Abstract (sommario):
Castration-resistant prostate cancer (CRPC) represents a final stage of this malignancy for many men and is defined as the progression of prostate cancer despite castrate levels of testosterone. CRPC may present as a rising PSA, the development of new metastases, or worsening of known metastases. Recent advances have resulted in five new treatments for CRPC: the immunotherapy sipuleucel-T; the cytotoxic cabazitaxel; the androgen biosynthesis inhibitor abiraterone acetate; the radioisotope radium-223; and the antiandrogen enzalutamide. These have all improved overall survival in randomized phase III studies for patients with metastatic CRPC. Furthermore, multiple agents and combinations are currently in late-stage clinical testing. Men with advanced prostate cancer represent an important population for clinical and translational research and clinical trial participation should be considered as part of standard care.
Gli stili APA, Harvard, Vancouver, ISO e altri
50

Thursfield, Rebecca, Chris Orchard, Rosanna Featherstone e Jane C. Davies. Future treatments. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198702948.003.0013.

Testo completo
Abstract (sommario):
There are only a relatively limited armoury of drugs, the majority of which are aimed at downstream symptoms of cystic fibrosis. Therapies targeting the basic defect in CF as well as continued availability of more conventional drugs are required. Progress in gene therapy has been limited by the significant barriers to gene transfer of the CF lung, but the UK is hosting a large repeated dose trial of nebulized non-viral gene therapy designed around clinically meaningful outcomes. The UK CF Gene Therapy Consortium is also seeking to develop a promising modified lentiviral approach, although this is some years off. Perhaps the exciting development of recent decades has come from small molecule CFTR modulators, driven by an understanding of basic pathophysiological mechanisms. Ivacaftor is the first drug to be licensed, having proved itself highly clinically efficacious in patients with the class-3 gating mutation G551D. The trial pipeline seeks to expand indications for this and to explore the potential of Phe508del correctors. Finally, a number of anti-inflammatory and anti-infective strategies are being pursued. The emerging global problem of antibiotic resistance is leading to exciting alternatives such as biofilm disruption and bacteriophage to be explored.
Gli stili APA, Harvard, Vancouver, ISO e altri
Ti possono interessare anche gli elenchi di altri tipi di fonti sul tema "Resistance to therapies":
Articoli di riviste Tesi
Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!

Vai alla bibliografia